GW Pharmaceuticals Plc (GWPH): Price and Financial Metrics


GW Pharmaceuticals Plc (GWPH)

Today's Latest Price: $156.31 USD

2.16 (-1.36%)

Updated Jan 28 11:11am

Add GWPH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 241 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GWPH Stock Summary

  • GWPH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 921.1 -- higher than 95.72% of US-listed equities with positive expected earnings growth.
  • The ratio of debt to operating expenses for Gw Pharmaceuticals Plc is higher than it is for about just 7.93% of US stocks.
  • Revenue growth over the past 12 months for Gw Pharmaceuticals Plc comes in at 133.62%, a number that bests 95.7% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Gw Pharmaceuticals Plc, a group of peers worth examining would be AIRG, SWAV, OOMA, PRO, and AEHR.
  • GWPH's SEC filings can be seen here. And to visit Gw Pharmaceuticals Plc's official web site, go to www.gwpharm.com.

GWPH Stock Price Chart Interactive Chart >

Price chart for GWPH

GWPH Price/Volume Stats

Current price $156.31 52-week high $162.87
Prev. close $158.47 52-week low $67.98
Day low $156.31 Volume 102,753
Day high $162.00 Avg. volume 419,276
50-day MA $128.07 Dividend yield N/A
200-day MA $116.50 Market Cap 4.85B

GW Pharmaceuticals Plc (GWPH) Company Bio


GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company was founded in 1998 and is based in Cambridge, the United Kingdom.


GWPH Latest News Stream


Event/Time News Detail
Loading, please wait...

GWPH Latest Social Stream


Loading social stream, please wait...

View Full GWPH Social Stream

Latest GWPH News From Around the Web

Below are the latest news stories about Gw Pharmaceuticals Plc that investors may wish to consider to help them evaluate GWPH as an investment opportunity.

Ovid Therapeutics: Residual Value In OV935 After The OV101 Fiasco

In August 2019, I wrote a somewhat negative article on Ovid Therapeutics (OVID) and its OV101 drug. I said that OV101 failed to meet statistical significance in a number of secondary efficacy endpoints in a phase 2 trial, so I doubted how it would fare in the then-ongoing phase 3...

Avisol Capital Partners on Seeking Alpha | January 18, 2021

The Week In Cannabis: Stocks Spike By Double Digits On Earnings, Strong Sales, Financings

Cannabis stocks widely outperformed the markets after a slew of financing deals and strong earnings reports."The cannabis industry is off to a great start this year with New York state pushing hard for legalization," Green Market Report editor-in-chief Debra Borchardt said. "In addition to that several companies like GrowGeneration and GW Pharmaceuticals reported stellar earnings. Plus, Subversive Capital closed on the largest SPAC in the industry. Hopefully, the good news in 2021 will continue unlike the curveball thrown at us in 2020."ETFs were all up by double digits. Over the last five trading days: * The ETFMG Alternative Harvest ETF (NYSE: MJ): gained almost 18% * The AdvisorShares Pure Cannabis ETF (NYSE: YOLO): was up almost 12% * The Cannabis ETF (NYSE: THCX): rose 18.4% * ...

Yahoo | January 16, 2021

GW Pharma expects fiscal 2020 sales to reach $526 million

United Kingdom-based GW Pharmaceuticals expects to report annual sales of approximately $526 million for the year ended Dec. 31, 2020, it said in a preview of its fourth quarter and full-year results. Fourth quarter net sales will be approximately $148 million, based on preliminary unaudited financial information, GW said in a news release this week. […] GW Pharma expects fiscal 2020 sales to reach $526 million is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Marijuana Business Daily | January 13, 2021

Cannabis Companies Entered 2021 With A Bang

The Democratic win that joined the wave of state legalization is encouraging for the cannabis market. Based on their most recent quarterly filing, Canopy Growth Corp (NASDAQ: CGC ), Cronos Group Inc (NASDAQ: CRON ), GW Pharmaceuticals PLC (NASDAQ: GWPH ), Aphria Inc (NASDAQ: APHA ) that announced it will merge with Tilray Inc (NASDAQ: TLRY ) in mid-December and Trulieve Cannabis Corp (OTC: TCNNF ), entered 2021 with the most cash on their balance sheets. But other stocks such as Curaleaf Holdings Inc (OTC: CURLF ), Cresco Labs Inc (OTC: CRLBF ), Planet 13 Holdings Inc (OTC: PLNHF ), Innovative Industrial Properties Inc (NYSE: IIPR ) and Green Thumb Industries Inc (OTC: GTBIF ) show a lot of potential as well, along with several powerful small caps. Being Cash-Rich Is Not Is As It Seems ...

Benzinga | January 13, 2021

39th Annual JPMorgan Virtual Healthcare Conference

The following slide deck was published by GW Pharmaceuticals plc in conjunction with this event....

SA Transcripts on Seeking Alpha | January 12, 2021

Read More 'GWPH' Stories Here

GWPH Price Returns

1-mo 36.03%
3-mo 73.66%
6-mo 22.47%
1-year 36.96%
3-year 11.92%
5-year 211.62%
YTD 35.44%
2020 10.38%
2019 7.36%
2018 -26.23%
2017 18.13%
2016 60.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0339 seconds.